Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases
- 23 April 2022
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 193 (3) , 613-623
Abstract
Purpose Leptomeningeal metastases (LM) are an aggressive complication of metastatic breast cancer (MBC) with brain metastases (BM), with a short survival of weeks to months. Studies suggest that surgical resection of BM may increase the risk of LM, especially in infratentorial metastases. In this retrospective study, we examine this and other factors which may be associated with increased risk of LM. Methods A database search at a single institution identified 178 patients with MBC and treated BM between 2007 and 2020. We collected demographic, clinical, radiographic, and other treatment data. LM was diagnosed by cerebrospinal fluid (CSF) cytology, neuroimaging, or both. Cox proportional hazards model was used. Results After a median follow-up of 8.5 months, 41 out of 178 patients (23%) with BM developed LM. Median time to develop LM was 130 days. Mean age was 51.3 years. The number and size of the BM, hemorrhagic/cystic lesions, progressive/stable systemic disease, and extracranial metastases sites other than liver did not pose a higher risk of LM. Infratentorial lesions (HR = 5.41) and liver metastases (HR = 2.28) had a higher risk of LM. Patients who had any surgery did not have a higher risk for LM (HR 1.13). The LM group had a worse overall survival as compared to the non-LM group. Conclusion Among MBC patients with BM, infratentorial BM and visceral liver lesions increase the risk of LM, whereas local treatment modalities such as surgery and radiation do not. These data imply that local treatment strategy should not differ based on potential risk for LM.Keywords
All Related Versions
Funding Information
- None
This publication has 13 references indexed in Scilit:
- Comparing Preoperative With Postoperative Stereotactic Radiosurgery for Resectable Brain MetastasesNeurosurgery, 2016
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic TargetsCancer Discovery, 2015
- Leptomeningeal disease following stereotactic radiosurgery for brain metastases from breast cancerJournal of Neuro-Oncology, 2015
- Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosisJournal of Neurosurgery, 2014
- Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survivalMedical Oncology, 2013
- Single-Dose Versus Fractionated Stereotactic Radiotherapy for Brain MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatmentJournal of Neuro-Oncology, 2011
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 StudyJournal of Clinical Oncology, 2011
- Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)Annals of Oncology, 2006
- Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000